Bisphosphonate plus chemotherapy ups chance for complete pathologic response

Article

The concept of bisphosphonates as anticancer agents took a leap forward this week thanks to results from the AZURE trial. Investigators from the UK reported that patients receiving zoledronic acid along with neoadjuvant chemotherapy experienced a doubling in complete pathological response.

SAN ANTONIO-The concept of bisphosphonates as anticancer agents took a leap forward this week thanks to results from the AZURE trial. Investigators from the UK reported that patients receiving zoledronic acid along with neoadjuvant chemotherapy experienced a doubling in complete pathological response.

"This is the first patient-related evidence that this class of drugs may have direct antitumor activity," said Robert Coleman, MD, of the University of Sheffield during an SABCS 2008 press conference (SABCS abstract 5101).

Interest in the antitumor effect of bisphosphonates is on the rise, based in large part on the improvement observed in disease-free survival for women receiving zoledronic acid along with endocrine therapy (ASCO 2008 abstract LBA-4).

The work by Dr. Coleman and colleagues was a component of the AZURE trial that enrolled 3,360 women with stage II or III breast cancer. They received zoledronic acid in addition to neoadjuvant therapy. A retrospective exploratory evaluation of patients who received zoledronic acid (4 mg IV) with chemotherapy found that complete pathologic responses nearly doubled to 10.9% compared with 5.8% with chemotherapy alone, after adjusting for confounders.

Residual invasive tumor size was reduced to 28 mm in the zoledronic acid arm from 42 mm in the chemotherapy-alone arm. The median number of positive lymph nodes was three in the chemotherapy arm and two in the zoledronic acid-plus-chemotherapy arm. Sixty-five percent of the women in the zoledronic acid arm required mastectomy (rather than breast-conserving surgery) compared with 78% in the chemotherapy alone arm.

Dr. Coleman said that these results add significantly to the data generated from the Austrian Breast and Colorectal Cancer Study Group. AZURE included patients treated with chemotherapy, not endocrine therapy, and, most important, the impact of the drug on breast tissue itself was observed.

"This is the first evidence in a human model of a direct effect of bisphosphonates within the cancer cell," he said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content